Muhammad Junaid Rashid
@mjunaidr.bsky.social
Pharmacist |M Phil Mol.Pharmacölogy| Enthusiastic to learn Functional Genømics of rare Cancer, Translational Precisioñ Øncology, & OnCo-Genetics- For PhD research 🛫🥨...
Reposted by Muhammad Junaid Rashid
🎄Wir wünschen euch schöne Feiertage!🎄
✨ Danke für eure tolle Unterstützung in diesem Jahr. 💝
#FroheWeihnachten #MerryChristmas2025
✨ Danke für eure tolle Unterstützung in diesem Jahr. 💝
#FroheWeihnachten #MerryChristmas2025
December 23, 2025 at 2:49 PM
🎄Wir wünschen euch schöne Feiertage!🎄
✨ Danke für eure tolle Unterstützung in diesem Jahr. 💝
#FroheWeihnachten #MerryChristmas2025
✨ Danke für eure tolle Unterstützung in diesem Jahr. 💝
#FroheWeihnachten #MerryChristmas2025
Reposted by Muhammad Junaid Rashid
@nct-heidelberg.bsky.social @dkfz.bsky.social DKTK HARPOON Symposium brought together leading experts from clinical & research settings to discuss cutting-edge advances in precision oncology, including key contributions from #CCE members @vhio.bsky.social @crukcamcentre.bsky.social @gustaveroussy.fr
December 2, 2025 at 10:19 AM
@nct-heidelberg.bsky.social @dkfz.bsky.social DKTK HARPOON Symposium brought together leading experts from clinical & research settings to discuss cutting-edge advances in precision oncology, including key contributions from #CCE members @vhio.bsky.social @crukcamcentre.bsky.social @gustaveroussy.fr
Reposted by Muhammad Junaid Rashid
Highlights from the inspiring #CCETRYTRAC meeting at @nct-heidelberg.bsky.social @dkfz.bsky.social
Learn more🔗 www.cancercoreeurope.eu/cce-trytrac-...
@nkinl.bsky.social @ki.se @crukcamcentre.bsky.social @vhio.bsky.social @gustaveroussy.fr
Learn more🔗 www.cancercoreeurope.eu/cce-trytrac-...
@nkinl.bsky.social @ki.se @crukcamcentre.bsky.social @vhio.bsky.social @gustaveroussy.fr
CCE TRYTRAC 2: Face-to-Face Meeting at NCT Heidelberg/DKFZ
Latest CCE TRYTRAC brought together professionals from CCE centers to exchange expertise in cutting-edge, patient-centered cancer research.
www.cancercoreeurope.eu
November 19, 2025 at 8:50 AM
Highlights from the inspiring #CCETRYTRAC meeting at @nct-heidelberg.bsky.social @dkfz.bsky.social
Learn more🔗 www.cancercoreeurope.eu/cce-trytrac-...
@nkinl.bsky.social @ki.se @crukcamcentre.bsky.social @vhio.bsky.social @gustaveroussy.fr
Learn more🔗 www.cancercoreeurope.eu/cce-trytrac-...
@nkinl.bsky.social @ki.se @crukcamcentre.bsky.social @vhio.bsky.social @gustaveroussy.fr
Reposted by Muhammad Junaid Rashid
It has been an honor for me to have worked in this fantastic project with great scientists and brilliant students for the last few years.
Chordomas are rare bone tumors for which there are currently no effective drugs. A research team from the DKFZ and @nct-heidelberg.bsky.social managed to block the central driver of tumor development and in the result slowed the growth of chordoma cells. #CancerResearch
t1p.de/h9izi
t1p.de/h9izi
Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers
Chordomas are rare bone tumors for which there are currently no effective drugs. A research team from the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelbe...
t1p.de
September 4, 2025 at 8:05 PM
It has been an honor for me to have worked in this fantastic project with great scientists and brilliant students for the last few years.
Reposted by Muhammad Junaid Rashid
"I had the rare #opportunity to be supported in my desire of exploring fundamental scientific questions (...). And today, as a member, I have the opportunity to act on a bigger scale," says @ilohmann.bsky.social, Professor @uniheidelberg.bsky.social and EMBO Member: www.embo.org/people/twent... 🧪
Twenty-five years of EMBO experiences – People – EMBO
An interview with Ingrid Lohmann, Professor of Developmental Biology, University of Heidelberg | EMBO Member
www.embo.org
August 9, 2025 at 8:05 AM
"I had the rare #opportunity to be supported in my desire of exploring fundamental scientific questions (...). And today, as a member, I have the opportunity to act on a bigger scale," says @ilohmann.bsky.social, Professor @uniheidelberg.bsky.social and EMBO Member: www.embo.org/people/twent... 🧪
Reposted by Muhammad Junaid Rashid
Read 'The long-term effects of chemotherapy on normal blood cells’ from @sangerinstitute.bsky.social, @cam.ac.uk, @cuh.nhs.uk @cancergrand.bsky.social & others in Nature Genetics ⤵️
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The long-term effects of chemotherapy on normal blood cells - Nature Genetics
Mutational signature analysis of blood cells isolated from 23 chemotherapy-exposed samples and 9 nonexposed controls characterizes the effects of various drugs on mutational burden, signature exposure...
www.nature.com
July 1, 2025 at 2:33 PM
Read 'The long-term effects of chemotherapy on normal blood cells’ from @sangerinstitute.bsky.social, @cam.ac.uk, @cuh.nhs.uk @cancergrand.bsky.social & others in Nature Genetics ⤵️
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Muhammad Junaid Rashid
Reposted by Muhammad Junaid Rashid
If you are at the #EACR2025 today and interested in integrative genomics of rare cancers, feel free to visit me by the poster P-006 in Pavilion 1 during the poster session.
June 18, 2025 at 11:48 AM
If you are at the #EACR2025 today and interested in integrative genomics of rare cancers, feel free to visit me by the poster P-006 in Pavilion 1 during the poster session.
Reposted by Muhammad Junaid Rashid
June 18, 2025 at 10:25 PM
Reposted by Muhammad Junaid Rashid
June 18, 2025 at 10:20 PM
Reposted by Muhammad Junaid Rashid
Jan H. Hoeijmakers shared mindblowing insights on how caloric restriction impact on DNA damage response, cancer, and ageing! Also unexpected effects of carbohydrate and fat vs protein intake. (Less) food for thought —literally!
#EACR2025
#EACR2025
June 17, 2025 at 9:41 AM
Reposted by Muhammad Junaid Rashid
Tune into episode 23 of The Cancer Researcher Podcast 🎙️
We chat with Chiara Pozzato & Georgia Konstantinidou (University of Bern) on FAK signalling in KRAS-driven NSCLC and a novel treatment angle.
🎧 Dive in: magazine.eacr.org/novel-approa...
We chat with Chiara Pozzato & Georgia Konstantinidou (University of Bern) on FAK signalling in KRAS-driven NSCLC and a novel treatment angle.
🎧 Dive in: magazine.eacr.org/novel-approa...
June 11, 2025 at 7:01 AM
Tune into episode 23 of The Cancer Researcher Podcast 🎙️
We chat with Chiara Pozzato & Georgia Konstantinidou (University of Bern) on FAK signalling in KRAS-driven NSCLC and a novel treatment angle.
🎧 Dive in: magazine.eacr.org/novel-approa...
We chat with Chiara Pozzato & Georgia Konstantinidou (University of Bern) on FAK signalling in KRAS-driven NSCLC and a novel treatment angle.
🎧 Dive in: magazine.eacr.org/novel-approa...
Reposted by Muhammad Junaid Rashid
Neuer Sonderforschungsbereich zu Krebserkrankungen des blutbildenden Knochenmarks: DFG fördert Forschungsverbund an der Medizinischen Fakultät Heidelberg mit rund 15,8 Millionen Euro www.uni-heidelberg.de/de/newsroom/...
#heidelberg #uniheidelberg #medizin #krebs #forschung #förderung @dfg.de
#heidelberg #uniheidelberg #medizin #krebs #forschung #förderung @dfg.de
May 30, 2025 at 9:43 AM
Neuer Sonderforschungsbereich zu Krebserkrankungen des blutbildenden Knochenmarks: DFG fördert Forschungsverbund an der Medizinischen Fakultät Heidelberg mit rund 15,8 Millionen Euro www.uni-heidelberg.de/de/newsroom/...
#heidelberg #uniheidelberg #medizin #krebs #forschung #förderung @dfg.de
#heidelberg #uniheidelberg #medizin #krebs #forschung #förderung @dfg.de
Reposted by Muhammad Junaid Rashid
We’re campaigning to #KeepResearchCurious because early-stage, curiosity-driven cancer research is the cornerstone of future medical breakthroughs 🔍 #EWAC2025
May 26, 2025 at 8:01 AM
We’re campaigning to #KeepResearchCurious because early-stage, curiosity-driven cancer research is the cornerstone of future medical breakthroughs 🔍 #EWAC2025
Reposted by Muhammad Junaid Rashid
Exciting times ahead! The first joint clinical trial of the National Center for Tumor Diseases #OneNCT will address the unresolved question of whether treatment based on multi-layered molecular profiling can improve outcomes in patients with advanced #RareCancers. nct.dkfz.de/en/nct/news/...
RATIONALE focuses on rare cancers
First multi-site study by the National Center for Tumor Diseases (NCT)
nct.dkfz.de
December 16, 2024 at 6:17 PM
Exciting times ahead! The first joint clinical trial of the National Center for Tumor Diseases #OneNCT will address the unresolved question of whether treatment based on multi-layered molecular profiling can improve outcomes in patients with advanced #RareCancers. nct.dkfz.de/en/nct/news/...
Reposted by Muhammad Junaid Rashid
Jetzt anmelden!
Der NCT-Lauf 2025 findet vom 11. bis 13. Juli statt – jede:r kann kostenlos mitmachen und die Krebsforschung unterstützen. Ob laufend, wandernd oder spazierend: Jeder Kilometer zählt. Unser gemeinsames Ziel: 40.000 Kilometer
Anmeldung und Infos www.nct-lauf.de
#nctlauf #nctrun
Der NCT-Lauf 2025 findet vom 11. bis 13. Juli statt – jede:r kann kostenlos mitmachen und die Krebsforschung unterstützen. Ob laufend, wandernd oder spazierend: Jeder Kilometer zählt. Unser gemeinsames Ziel: 40.000 Kilometer
Anmeldung und Infos www.nct-lauf.de
#nctlauf #nctrun
May 22, 2025 at 11:46 AM